IL-12-Producing Cytokine Factories Induce Precursor Exhausted T Cells and Elimination of Primary and Metastatic Tumors

Researchers evaluated the safety and antitumor efficacy of locally administered interleukin 12 (IL-12) using a clinically translatable cytokine delivery platform to identify Tpex recruitment capabilities at tolerable cytokine doses.